First Time Loading...

Gain Therapeutics Inc
NASDAQ:GANX

Watchlist Manager
Gain Therapeutics Inc Logo
Gain Therapeutics Inc
NASDAQ:GANX
Watchlist
Price: 2.92 USD 0.69%
Updated: May 8, 2024

Gain Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gain Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Gain Therapeutics Inc
NASDAQ:GANX
Cash from Financing Activities
$12.6m
CAGR 3-Years
6%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$2.2B
CAGR 3-Years
31%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.4B
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Gain Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
12.6m USD

Based on the financial report for Dec 31, 2023, Gain Therapeutics Inc's Cash from Financing Activities amounts to 12.6m USD.

What is Gain Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
67%

The average annual Cash from Financing Activities growth rates for Gain Therapeutics Inc have been 6% over the past three years , 67% over the past five years .